Novasep
| Industry | Pharmaceutical supplier |
|---|---|
| Founded | c. 1995 |
| Founder | Michel Spagnol |
| Headquarters | , France |
| Revenue | EUR 271 million[1] (2016[1]) |
Number of employees | 1200[2] (2017[2]) |
| Website | www |
Novasep, based in Lyon (France), is a group of companies involved in pharmaceutical and biopharmaceutical technologies.
History
[edit]The company emerged as a start-up founded by Roger-Marc Nicoud c. 1995, producing pharmaceuticals, biopharmaceuticals, and purification technologies for food markets.[3]
Novasep was privately owned until 2005 before it was sold to the American Rockwood group. In 2005, the major investments were made with Rockwood as an investment partner. As of 2007, the private equity investors Gilde Buy-Out Partners and Banexi Capital Partenaires will hold 72 percent of Groupe Novasep, with management's share increasing to 28 percent. In 2011, as a result of the financial crisis, the company's debts of 450 million euros had to be restructured; this brought the company's capital through a haircut and debt stake swap into the hands of the American investors Tennenbaum, Silver Point and Pimco. The founder subsequently left the company and new management was appointed; the headquarters was moved from Pompey in Lorraine to Lyon.[3]
Novasep's Belgium viral vector manufacturing division, Henogen, was sold to Thermo Fisher for €725 million in January 2021.[4][5] Later that month it was announced by AstraZeneca that production difficulties at the Belgium plant meant supplies of the Oxford–AstraZeneca COVID-19 vaccine to the European Union would be less than the 80m doses expected be supplied to March 2021.[6]
References
[edit]Footnotes
[edit]- ^ a b Novasep (2017a).
- ^ a b Novasep (2017b).
- ^ a b Henrion (2014).
- ^ Hale (2021).
- ^ Mullin (2021).
- ^ Agencies (2021).
Sources
[edit]- Agencies (22 January 2021). "Covid: Oxford/AstraZeneca vaccine delivery to EU to be cut by 60%". The Guardian. Retrieved 23 January 2021.
- "Pressemeldung Novasep zum Ergebnis 2016" [Novasep publishes financial results for 2016] (PDF). Novasep (in German). 31 May 2017a.
- "About". Novasep. 2017b.
- Hale, Conor (15 January 2021). "JPM: Thermo Fisher picks up Novasep's viral vector business for $878M outright". FierceBiotech. Retrieved 29 November 2021.
- Henrion, Audrey (4 July 2014). "Novasep. Lyon comme base de redéploiement" [Novasep. Lyon as a redeployment base]. Les Journal des Enterprises (in French). Archived from the original on 11 July 2014.
- Mullin, Rick (15 January 2021). "Thermo Fisher strikes again in viral vectors". cen.acs.org. Retrieved 29 November 2021.